Results 21 to 30 of about 26,737 (201)

Pyrazinamide may possess cardioprotective properties [PDF]

, 2019
Pyrazinamide is an anti-tubercular agent, used as a part of a three-drug regime (any three of the following: rifampicin, isoniazid, pyrazinamide, streptomycin or ethambutol) for the initial phase of treatment.
Sukhodub, Andriy, Du, Qingyou, Sinha, Sharabh, Sofija Jovanović, Jovanovic, Sofija, Aleksandar Jovanović, Sharabh Sinha, Andriy Sukhodub, Qingyou Du, Jovanović, Aleksandar   +9 more
core   +1 more source

Relative Stability of Pyrazinamide Polymorphs Revisited: A Computational Study of Bending and Brittle Forms Phase Transitions in a Broad Temperature Range

Crystals, 2023
Pyrazinamide may exist in at least four known polymorphic forms, which were obtained experimentally. One of these polymorphs, (α), shows outstanding mechanical properties, demonstrating a significant anisotropic plasticity in a three-point bending test ...
Aleksandr S. Dubok, Denis A. Rychkov
doaj   +1 more source

Is the Pharmacokinetics of First-Line Anti-TB Drugs a Cause of High Mortality Rates in TB Patients Admitted to the ICU? A Non-Compartmental Pharmacokinetic Analysis

Tropical Medicine and Infectious Disease, 2023
Background: Patients with tuberculosis (TB) may develop multi-organ failure and require admission to intensive care. In these cases, the mortality rates are as high as 78% and may be caused by suboptimal serum concentrations of first-line TB drugs.
Francisco Beraldi-Magalhaes, Suzanne L. Parker, Cristina Sanches, Leandro Sousa Garcia, Brenda Karoline Souza Carvalho, Amanda Araujo Costa, Mariana Millan Fachi, Marcus Vinicius de Liz, Alexandra Brito de Souza, Izabella Picinin Safe, Roberto Pontarolo, Steven Wallis, Jeffrey Lipman, Jason A. Roberts, Marcelo Cordeiro-Santos   +14 more
doaj   +1 more source

Determination of pyrazinamide plasma concentrations using lc-ms and pharmacokinetics of pyrazinamide in patients with multidrug-resistant tuberculosis and in patients co-infected with multidrug-resistant tuberculosis and HIV [PDF]

, 2013
Magister Pharmaceuticae - MPharmTuberculosis and HIV are arguably South Africa’s largest and most important health issues. With drug-resistant strains of tuberculosis on the increase and little research on new drugs, there is an urgent need for research ...
Botha, Carla Ilse
core   +1 more source

Obstructive Jaundice due to a Periportal Tuberculous Mass Complicated by Anti-Tuberculous Drug-Induced Liver Injury: A Case Report From a Low-Resource Setting. [PDF]

Clin Case Rep
ABSTRACT Periportal tuberculous lymphadenitis with obstructive jaundice is rare and may mimic malignancy. We report a case of obstructive jaundice caused by a periportal tuberculous mass confirmed by fine‐needle aspiration and GeneXpert. Treatment was complicated by anti‐tuberculous drug‐induced liver injury.
Lema GD, Chanie Y, Yanore MT, Mengistu SB, Kotisso AB, Zena D, Gebreeyesus ST, Gared TM, Chekol NS, Muhammed EU.   +9 more
europepmc   +2 more sources

Pyrazinamide-induced acute gouty arthritis: a case report [PDF]

, 2022
Gout is a common inflammatory and metabolic disease caused by the deposition of monosodium urate crystals in articular and non-articular tissues. Drugs used to treat tuberculosis, such as pyrazinamide and ethambutol, have been linked to hyperuricaemia ...
Emorinken, Airenakho, Ugheoke, Asuwemhe J.   +1 more
core   +1 more source

Analysis of rpoB and pncA mutations in the published literature: an insight into the role of oxidative stress in Mycobacterium tuberculosis evolution? [PDF]

, 2005
Introduction: It is perceived wisdom that within the host macrophage, Mycobacterium tuberculosis frequently encounters oxidative stress. Exposure of bacteria to reactive oxygen intermediates can have a mutagenic effect on the DNA.
O'Sullivan, DM, O'Sullivan, D M, McHugh, TD, Timothy D. McHugh, O'Sullivan, Denise M, Gillespie, S H, Gillespie, Stephen H, Gillespie, SH, Stephen H. Gillespie, McHugh, Timothy D, Denise M. O'Sullivan, McHugh, T D   +11 more
core   +1 more source

Design, Synthesis, Antimycobacterial Evaluation, and In Silico Studies of 3-(Phenylcarbamoyl)-pyrazine-2-carboxylic Acids

Molecules, 2017
Pyrazinamide, the first-line antitubercular drug, has been regarded the basic component of tuberculosis treatment for over sixty years. Researchers have investigated its effect on Mycobacterium tuberculosis for this long time, and as a result, new ...
Lucia Semelková, Petra Janošcová, Carlos Fernandes, Ghada Bouz, Ondřej Janďourek, Klára Konečná, Pavla Paterová, Lucie Navrátilová, Jiří Kuneš, Martin Doležal, Jan Zitko   +10 more
doaj   +1 more source

Efficacy of Preventive Chemotherapy of Tuberculosis in HIV Infected Patients in Novosibirsk Oblast

Туберкулез и болезни лёгких, 2023
The objective: to study the efficacy of tuberculosis preventive chemotherapy in HIV infected patients based on the data of AIDS Prevention and Control Center, which is a part of City Infectious Clinical Hospital no.
D. V. Kapustin, E. I. Krasnova, N. I. Khokhlova, Yu. A. Stashevskaya, E. S. Pudova, L. L. Pozdnyakova   +5 more
doaj   +1 more source

Mutations in Efflux Pump Rv1258c (Tap) Cause Resistance to Pyrazinamide, Isoniazid, and Streptomycin in M. tuberculosis

Frontiers in Microbiology, 2019
Although drug resistance in Mycobacterium tuberculosis is mainly caused by mutations in drug activating enzymes or drug targets, there is increasing interest in the possible role of efflux in causing drug resistance.
Jiayun Liu, Jiayun Liu, Wanliang Shi, Shuo Zhang, Xiaoke Hao, Dmitry A. Maslov, Kirill V. Shur, Olga B. Bekker, Valery N. Danilenko, Ying Zhang   +9 more
doaj   +1 more source